Biosignal to expand furanone applications
06 September, 2004 by Melissa TrudingerBiosignal (ASX:BOS) will test its anti-bacterial compounds for activity against several species of oral bacteria, in a study that could open up a previously unexplored market niche for the company in the oral health sector.
Sunshine Heart to raise $15m in IPO
03 September, 2004 by Melissa TrudingerSunshine Heart is preparing to float on the ASX, launching a AUD$15 million IPO in Australia and New Zealand last week to raise funding to support its upcoming clinical trials.
LCT gains ground in ASX float
02 September, 2004 by Melissa TrudingerLiving Cell Technologies (ASX: LCT) gained 25 per cent on its issue price to close at AUD$0.25 yesterday on its first day of trading on the ASX.
Queensland govt claims a share of bioprospecting
02 September, 2004 by Renate KrelleThe Queensland parliament has passed legislation which allows the Queensland government to regulate the collection of native biological materials for molecular, biochemical or genetic analysis.
Cryptome receives $1.9m Start grant
02 September, 2004 by Melissa TrudingerCryptome Pharmaceuticals (ASX: CRP) has been awarded an R&D START grant from the Federal government to take its first lead compound, a naturally occurring peptide with anti-coagulant properties, through pre-clinical development and into the clinic for treatment of thrombosis and related cardiovascular conditions.
Emerging therapies to get a class of their own
01 September, 2004 by Renate KrelleOnce upon a time, biological therapies were plant extracts, tinctures and pills. Physicians also had at their disposal a variety of medical devices. But as new technologies have emerged in the last few years the boundaries between these categories have become increasingly blurred and novel therapies such as pancreatic islet transplantation, haemopoietic stem cells and cellular based vaccines have presented themselves for categorisation by the Therapeutic Goods Administration, under a regime which had, perhaps, become a little outmoded.
Bristol-Meyers Squibb warms to Cryosite
01 September, 2004 by Graeme O'NeillMultinational pharma Bristol-Myers Squibb has engaged Sydney-based cryogenic-storage company Cryosite (ASX:CTE) to manage its clinical trial supply logistics in Australia and New Zealand.
Colltech begins work on extraction plant
01 September, 2004 by Graeme O'NeillIf Australia rides on the sheep’s back, new Perth biotech CollTech (ASX:CAU) is capitalising on what lies just beneath the golden fleece: collagen-rich sheepskin.
Medimmune stops arthritis and psoriasis trials
31 August, 2004 by Staff WritersMaryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.
In brief: Agenix files for Canadian trials; Rockeby to appoint Chinese distributor
31 August, 2004 by Renate KrelleBrisbane’s Agenix (ASX: AGX, NASDAQ OTC: AGXLY) announced today it had filed a Clinical Trial Application (CTA) with Health Canada in preparation for the Phase II clinical trials of its ThromboView blood clot imaging technology.
ChemGenex and UK’s Vernalis sign $2m partnership
31 August, 2004 by Graeme O'NeillDeakin University molecular geneticist Professor Greg Collier was right on the mark when he chose the chubby Israeli sand rat as a model species for his quest for susceptibility genes for non insulin-dependent diabetes.
Investors stampede out of Chemeq
30 August, 2004 by Graeme O'NeillThe share price of Perth veterinary drug-developer Chemeq Ltd (ASX:CMQ) lost over 25 per cent of its value when the company resumed trading today after a two-week voluntary suspension.
Biota winds back loss, despite legal expenses
30 August, 2004 by Renate KrelleMelbourne-based Biota (ASX:BTA) has reported a loss of $7.8 million, down 25 per cent from its 2003 loss of $10.3 million. This is despite a hefty legal bill of just under $1 million for Biota’s lawsuit against marketing partner GlaxoSmithKline for failure to promote its influenza drug, Relenza.
Agenix files IND, announces $14.3m loss
30 August, 2004 by Renate KrelleBrisbane’s Agenix [ASX: AGX, NASDAQ OTC: AGXLY] has filed an Investigational New Drug application with the US Food and Drug Administration for its blood clot imaging technology, Thromboview.
Solid Progen looking to bolster pipeline
30 August, 2004 by Graeme O'NeillBrisbane cancer-drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) has reported a reduced net loss of AUD$4.8 million for the year to June 30, down from $7.6 million in 2003, after increasing revenues by 8.6 per cent.
